A systems approach to designing next generation vaccines: Combining α-galactose modified antigens with nanoparticle platforms

Yashdeep Phanse, Brenda R. Carrillo-Conde, Amanda E. Ramer-Tait, Scott Broderick, Chang Sun Kong, Krishna Rajan, Ramon Flick, Robert B. Mandell, Balaji Narasimhan, Michael J. Wannemuehler

Research output: Contribution to journalArticle

23 Scopus citations


Innovative vaccine platforms are needed to develop effective countermeasures against emerging and re-emerging diseases. These platforms should direct antigen internalization by antigen presenting cells and promote immunogenic responses. This work describes an innovative systems approach combining two novel platforms, αGalactose (αGal)-modification of antigens and amphiphilic polyanhydride nanoparticles as vaccine delivery vehicles, to rationally design vaccine formulations. Regimens comprising soluble αGal-modified antigen and nanoparticle-encapsulated unmodified antigen induced a high titer, high avidity antibody response with broader epitope recognition of antigenic peptides than other regimen. Proliferation of antigen-specific CD4 + T cells was also enhanced compared to a traditional adjuvant. Combining the technology platforms and augmenting immune response studies with peptide arrays and informatics analysis provides a new paradigm for rational, systems-based design of next generation vaccine platforms against emerging and re-emerging pathogens.

Original languageEnglish (US)
Article number3775
JournalScientific reports
Publication statusPublished - Jan 20 2014


ASJC Scopus subject areas

  • General

Cite this